Literature DB >> 2571326

Changing therapy from timolol to betaxolol. Effect on intraocular pressure in selected patients with glaucoma. Timolol-Betaxolol Study Group.

R Vogel1, R Tipping, S F Kulaga, C M Clineschmidt.   

Abstract

Three hundred fifty-three patients whose intraocular pressure was controlled with a timolol maleate ophthalmic solution were studied. Following a baseline period, half were switched (masked and randomized) to treatment with a betaxolol hydrochloride ophthalmic solution and were followed up for 12 weeks. Intraocular pressure, signs, and symptoms were recorded at weeks 1, 4, 8, and 12. Those patients switched to the betaxolol ophthalmic solution had a significant increase in both ocular side effects (burning/stinging and tearing) and intraocular pressure at weeks 4, 8, and 12 when compared with those patients who continued to receive timolol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571326     DOI: 10.1001/archopht.1989.01070020373038

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

Review 1.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

2.  Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine.

Authors:  A L Robin
Journal:  Trans Am Ophthalmol Soc       Date:  1996

3.  Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: Does a central electronic medical record make a difference?

Authors:  Shlomo Vinker; Igor Kaiserman; Dan Andrei Waitman; Shimon Blackman; Eliezer Kitai
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 4.  Current concepts of pharmacotherapy in hypertension--ophthalmically administered beta blockers and their cardiopulmonary effects.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.